Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.54 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751553 | 0.91 | GPR119 (0.53) | GPR119 | |
| SCHEMBL30751541 | 0.91 | GPR119 (0.53) | GPR119 | |
| SCHEMBL30751496 | 0.89 | CAMK1D (0.43) | GPR119CAMK1DMAP4K1NR1H2 | |
| SCHEMBL30751488 | 0.88 | JAK2 (0.49) | GPR119MAP4K1 | |
| SCHEMBL30751544 | 0.84 | PTPN11 (0.52) | GPR119PTPN11CAMK1DMAP4K1 | |
| SCHEMBL30751563 | 0.81 | GPR119 (0.43) | GPR119SMARCA2SMARCA4PBRM1CAMK1D | |
| SCHEMBL30751572 | 0.81 | GPR119 (0.43) | GPR119SMARCA2SMARCA4PBRM1CAMK1D | |
| SCHEMBL30751549 | 0.80 | TYK2 (0.47) | GPR119NR1H2 | |
| Hydrochloric Acid SCHEMBL30751516 | 0.79 | KHK (0.42) | CAMK1DMAP4K1 | |
| SCHEMBL30751499 | 0.79 | GPR119 (0.46) | GPR119CAMK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC (US) | 2025-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | GPR119 604/4885SMARCA2 3206/4885SMARCA4 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.